

# Xu Chao Zhang

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4377475/xu-chao-zhang-publications-by-citations.pdf>  
**Version:** 2024-04-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55 papers	1,241 citations	17 h-index	34 g-index
64 ext. papers	1,674 ext. citations	5.8 avg, IF	3.85 L-index

#	Paper	IF	Citations
55	Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2011</b> , 29, 3316-21	2.2	184
54	Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. <i>PLoS ONE</i> , <b>2012</b> , 7, e40109	3.7	136
53	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2235-2245	2.2	94
52	Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. <i>Cancer Prevention Research</i> , <b>2015</b> , 8, 165-73	3.2	88
51	Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1668-1675	8.9	63
50	PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells. <i>Oncolmmunology</i> , <b>2017</b> , 6, e1284722	7.2	58
49	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 311-9	7.5	55
48	Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor Cells. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5480-5488	12.9	52
47	Acquired Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4929-4937	12.9	50
46	In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 637-46	3.5	48
45	Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 18	22.4	46
44	Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 68	22.4	43
43	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. <i>MAbs</i> , <b>2018</b> , 10, 1301-1311	6.6	37
42	Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. <i>Lung Cancer</i> , <b>2018</b> , 125, 86-92	5.9	31
41	Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. <i>Journal of Hematology and Oncology</i> , <b>2011</b> , 4, 5	22.4	22
40	Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. <i>Biomarker Research</i> , <b>2020</b> , 8, 19	8	17
39	Lung cancer treatment disparities in China: a question in need of an answer. <i>Oncologist</i> , <b>2014</b> , 19, 1084-90	9.7	17

38	Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients. <i>Lung Cancer</i> , <b>2017</b> , 114, 90-95	5.9	15
37	Clinical characteristics and prognostic value of the mutation in Chinese non-small cell lung cancer patients. <i>Biomarker Research</i> , <b>2020</b> , 8, 22	8	14
36	DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells. <i>OncImmunology</i> , <b>2019</b> , 8, e1509173	7.2	14
35	Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 1512-1521	3.2	14
34	Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1093-1103	3.2	11
33	The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma. <i>Journal of Thoracic Disease</i> , <b>2015</b> , 7, 1630-6	2.6	10
32	Correlation of exosomal microRNA clusters with bone metastasis in non-small cell lung cancer. <i>Clinical and Experimental Metastasis</i> , <b>2021</b> , 38, 109-117	4.7	10
31	Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 85-91	4.9	9
30	Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. <i>Nature Communications</i> , <b>2021</b> , 12, 6450	17.4	9
29	A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases. <i>Lung Cancer</i> , <b>2019</b> , 131, 134-138	5.9	7
28	Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma-like carcinoma. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 346-352	3.2	7
27	Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinoma. <i>Oncology Letters</i> , <b>2016</b> , 11, 213-223	2.6	7
26	Predictive and Prognostic Potential of TP53 in Patients With Advanced Non-Small-Cell Lung Cancer Treated With EGFR-TKI: Analysis of a Phase III Randomized Clinical Trial (CTONG 0901). <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 100-109.e3	4.9	7
25	Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells. <i>Oncogene</i> , <b>2021</b> , 40, 1476-1489	8.2	7
24	Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis. <i>Journal of Thoracic Disease</i> , <b>2015</b> , 7, 1205-12	2.6	6
23	Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2717-2722	3.2	6
22	CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1713	8.4	4
21	Establishment and application of a multiplex genetic mutation-detection method of lung cancer based on MassARRAY platform. <i>Cancer Biology and Medicine</i> , <b>2016</b> , 13, 68-76	5.2	4

20	Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. <i>European Journal of Cancer</i> , <b>2021</b> , 150, 23-30	7.5	4
19	Synergistic antitumor activity of pro-apoptotic agent PAC-1 with cisplatin by the activation of CASP3 in pulmonary adenocarcinoma cell line H1299. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2016</b> , 12, 41-51	1.9	4
18	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. <i>Cancer Immunology, Immunotherapy</i> , <b>2018</b> , 67, 471-481	7.4	4
17	Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome Sequencing. <i>Journal of Genetics and Genomics</i> , <b>2015</b> , 42, 579-587	4	3
16	Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism. <i>Clinical and Translational Medicine</i> , <b>2020</b> , 10, 337-345	5.7	3
15	Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1 CD8 and CD8 T cells as predictive of response to neoadjuvant chemotherapy in breast cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2941-2954	3.2	3
14	High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2564-2573	3.2	3
13	MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. <i>Experimental Hematology and Oncology</i> , <b>2021</b> , 10, 52	7.8	2
12	Real-World Survival Outcomes Based on Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.. <i>JTO Clinical and Research Reports</i> , <b>2022</b> , 3, 100257	1.4	2
11	Comparative analysis of target gene exon sequencing by cognitive technology using a next generation sequencing platform in patients with lung cancer. <i>Molecular and Clinical Oncology</i> , <b>2021</b> , 14, 36	1.6	2
10	Association of Cerebrospinal Fluid Tumor DNA Genotyping With Survival Among Patients With Lung Adenocarcinoma and Central Nervous System Metastases. <i>JAMA Network Open</i> , <b>2020</b> , 3, e209077	10.4	2
9	Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.. <i>Cancer Discovery</i> , <b>2022</b> , OF1-OF12	24.4	2
8	Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer. <i>Chinese Medical Journal</i> , <b>2017</b> , 130, 1446-1453	2.9	1
7	A prospective phase II study of induction erlotinib therapy in stage IIIA-N2 non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7039-7039	2.2	1
6	Identification of leptomeningeal metastasis-specific exosomal miRNA signature in cerebrospinal fluid of non-small-cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21024-e21024	2.2	1
5	Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 5822-5832	2.6	1
4	Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , <b>2021</b> , 26, 100297	2	1
3	Response to tyrosine kinase inhibitors in advanced non-small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 9054-9054	2.2	0

- 2 TMB and TCR Are Correlated Indicators Predictive of the Efficacy of Neoadjuvant Chemotherapy in Breast Cancer.. *Frontiers in Oncology*, **2021**, 11, 740427 5.3 0
- 1 Establishment and application of a method of next generation sequencing of 285 genes in lung cancer based on Ion-Proton platform.. *Translational Cancer Research*, **2020**, 9, 4239-4249 0.3